Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

r-related death in men and women in the U.S., with 160,000 deaths estimated in 2007. Approximately 80 to 85 percent of these patients will be diagnosed with NSCLC, with the majority being diagnosed with locally advanced or metastatic disease.

About ERBITUX(R) (Cetuximab)

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.

ERBITUX is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) in combination with irinotecan for patients who are refractory to irinotecan-based chemotherapy, and as a single agent for patients who are intolerant to irinotecan-based therapy. The effectiveness of ERBITUX for the treatment of EGFR-expressing mCRC cancer is based on obj
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 2Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 4Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 1Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 2Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 3Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 4Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 5PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 1PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 2PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 3PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 4PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 5Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 59738 1Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 59738 2Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 59738 3
Breaking Medicine News(10 mins):Health News:BioVeda Health and Wellness Center of Spring Hill, TN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Spring Hill, TN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Spring Hill, TN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Spring Hill, TN Announces Its Grand Opening 5Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 2Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 3Health News:TouchSurfaces.Org Launches Public Health Information Site for Advanced Disinfectant Solutions for Use Around Children and Pets 2Health News:TouchSurfaces.Org Launches Public Health Information Site for Advanced Disinfectant Solutions for Use Around Children and Pets 3Health News:Registered Dietitians Identify Diet 'Gaps' - and How to Handle Them 2Health News:Registered Dietitians Identify Diet 'Gaps' - and How to Handle Them 3Health News:The New York Eye and Ear Infirmary Announces Partnership with ZocDoc 2